Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson, Ann‐Lii Cheng, Won Young Tak et al.|Journal of Clinical Oncology|2013

Cited by 775